氟-18标记氟昔洛韦PET/CT在临床实践中应用:影响复发性前列腺癌检出率的因素
该回顾性队列研究纳入152例初始治疗后疑似生化复发的前列腺癌患者,行商用18F-氟昔洛韦PET/CT,全身阳性率为81%(123/152),前列腺及前列腺床为61%(92/152),前列腺外为55%(83/152);阳性率随PSA水平升高呈线性增加(p<0.001),前列腺外阳性率随Gleason评分每增加1分优势增加49%(p<0.05)。
要点
- 全身阳性率81%(123/152),前列腺及前列腺床61%(92/152),前列腺外55%(83/152)。
- PSA<1 ng/mL阳性率58%(32/55),1–<2 ng/mL为87%(13/15),2–<5 ng/mL为100%(39/39),≥5 ng/mL为92%(35/38)。
- Gleason评分每增加1分,前列腺外阳性发现的优势增加49%(p<0.05)。
核心结论
- 商用18F-氟昔洛韦PET/CT对前列腺癌复发检出阳性率高,且与PSA水平升高正相关;对前列腺外病变,阳性率随Gleason评分升高而增加。
研究设计与样本
- 回顾性队列研究,纳入152例初始治疗后疑似生化复发的前列腺癌男性患者,均行18F-氟昔洛韦PET/CT。
- 计算全身、前列腺及前列腺床、前列腺外部位的阳性率。
- 评估绝对PSA水平、PSA动力学、Gleason评分及Gleason分级分组对阳性率的影响。
诊断标准与关键数值
- 全身阳性率81%(123/152),前列腺及前列腺床阳性率61%(92/152),前列腺外阳性率55%(83/152)。
- 全身阳性率随PSA水平升高呈线性增加(p<0.001)。
- PSA<1 ng/mL、1–<2 ng/mL、2–<5 ng/mL、≥5 ng/mL的全身阳性率分别为58%(32/55)、87%(13/15)、100%(39/39)、92%(35/38)。
- 阳性率与PSA水平倍增时间之间无统计学显著线性趋势(p>0.05)。
- 阳性率与Gleason分级分组升高之间无统计学显著线性趋势。
临床应用与阅片要点
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE. The purpose of this study is to show the performance and evaluate the factors influencing the positivity rate (PR) of commercially produced 18F-fluciclovine PET/CT in the detection of recurrent prostate cancer in clinical practice. MATERIALS AND METHODS. We performed a retrospective cohort study of 152 men who had suspected biochemical recurrence of prostate cancer after receiving initial treatment and underwent fluciclovine PET/CT. PRs were calculated for whole-body, prostate and prostate bed, and extraprostatic locations. The influence of different factors, such as the absolute prostate-specific antigen (PSA) level, PSA kinetics, the Gleason score, and Gleason grade groups, on the PR was evaluated. RESULTS. The overall PR was 81% (123/152) for the whole body, 61% (92/152) for the prostate and prostate bed, and 55% (83/152) for extraprostatic locations. There was a linear increase in the PR with an increasing PSA level (p < 0.001). For the whole body, the PR for PSA levels of less than 1 ng/mL, 1 to less than 2 ng/mL, 2 to less than 5 ng/mL, and 5 or more ng/mL were 58% (32/55), 87% (13/15), 100% (39/39), and 92% (35/38), respectively. No statistically significant linear trend was found between the PR and the PSA level doubling time (p > 0.05). In addition, no statistically significant linear trend was found between the PR and increasing Gleason grade group. However, for every 1-unit increase in a patient's Gleason score, the odds of a positive finding in the extraprostatic location increased by 49% (p < 0.05). CONCLUSION. Commercially produced fluciclovine PET/CT has a high PR for detection of prostate cancer recurrence and is positively correlated with increasing PSA levels. For extraprostatic disease, the PR increases with higher Gleason scores.
引用
- Savir-Baruch B, Lovrec P, Solanki AA, et al. Fluorine-18-Labeled Fluciclovine PET/CT in Clinical Practice: Factors Affecting the Rate of Detection of Recurrent Prostate Cancer. AJR Am J Roentgenol. 2019. PMID: 31216198. doi:10.2214/AJR.19.21153
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。